The blockade of hypoxia-stimulated glycolysis by ULK1/2 deficiency is a common feature not restricted to PDAC as such phenomena were also observed in hepatocellular carcinoma (HCC) HepG-2 and breast cancer (BC) MCF-7 cells (P < 0.01 and P < 0.05, Figure S1D-I), implying that ULK1/2 is indispensable for the hypoxic glycolysis of solid cancer cells. Here, ULK1 is linked to breast cancer.